Biotechs Aim for Public Markets with Less Cash in their Coffers
This article was originally published in Start Up
Executive Summary
An analysis of the total private money raised by US biotechs that have managed to squeeze through the public financing window since it reopened in 2003 shows that in general, better funded private companies have had an edge over less well funded firms when making it to the public markets-they hit the public financing window first and their VC investors have had to put up with less dilution.